Mitochondrial apoptosis and BH3 mimetics

The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Haiming, Meng, X. Wei, Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133681/
https://www.ncbi.nlm.nih.gov/pubmed/27990281
http://dx.doi.org/10.12688/f1000research.9629.1
_version_ 1782471315822739456
author Dai, Haiming
Meng, X. Wei
Kaufmann, Scott H.
author_facet Dai, Haiming
Meng, X. Wei
Kaufmann, Scott H.
author_sort Dai, Haiming
collection PubMed
description The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.
format Online
Article
Text
id pubmed-5133681
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-51336812016-12-16 Mitochondrial apoptosis and BH3 mimetics Dai, Haiming Meng, X. Wei Kaufmann, Scott H. F1000Res Review The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent. F1000Research 2016-12-01 /pmc/articles/PMC5133681/ /pubmed/27990281 http://dx.doi.org/10.12688/f1000research.9629.1 Text en Copyright: © 2016 Dai H et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Dai, Haiming
Meng, X. Wei
Kaufmann, Scott H.
Mitochondrial apoptosis and BH3 mimetics
title Mitochondrial apoptosis and BH3 mimetics
title_full Mitochondrial apoptosis and BH3 mimetics
title_fullStr Mitochondrial apoptosis and BH3 mimetics
title_full_unstemmed Mitochondrial apoptosis and BH3 mimetics
title_short Mitochondrial apoptosis and BH3 mimetics
title_sort mitochondrial apoptosis and bh3 mimetics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133681/
https://www.ncbi.nlm.nih.gov/pubmed/27990281
http://dx.doi.org/10.12688/f1000research.9629.1
work_keys_str_mv AT daihaiming mitochondrialapoptosisandbh3mimetics
AT mengxwei mitochondrialapoptosisandbh3mimetics
AT kaufmannscotth mitochondrialapoptosisandbh3mimetics

Ejemplares similares